## SLAB: Silicon Laboratories, Inc. - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (79th pct) cross-sectional ranking. Short-term MRS_5 (0.5%) confirms momentum alignment. Outperforming sector by 2.7%. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($133.43)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.02M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- FMR, LLC: 15.0% (+0.8%)
- Blackrock Inc.: 13.7% (+2.5%)
- Vanguard Group Inc: 11.8% (+1.9%)
- State Street Corpora: 4.7% (+2.4%)
- Macquarie Group Limi: 3.0% (-8.6%)

### Key Risks

1. Valuation stretched: PEG 3.0x requires aggressive growth execution.
2. Elevated short interest (9.4%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.03 signals overvaluation risk, limited margin of safety. Forward P/E 53.1x attractive for 197% earnings growth. Balance sheet: strong liquidity (4.5x), low leverage (D/E 0.17). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 1.56 |
| 52W Range | $82.82 - $160.00 |
| Short Interest | 9.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.03 |
| Forward P/E | 53.1 |
| Current P/E | 157.8 |
| YoY Growth | 197.1% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 7.7% to 3.9% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 79th percentile. MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.33), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.87% (CS: 79) | Strong |
| RSI_14 | 65.4 | Neutral |
| MACD Histogram | 2.33 | Bullish |
| vs SMA20 | 1.110x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $142.97
- **Stop Loss:** $133.43 (6.7% risk)
- **Target:** $157.28 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 144
- **Position Value:** $20,587.68
- **Portfolio %:** 20.59%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $0.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.32 | +4.2% |
| 2025Q2 | $0.09 | $0.11 | +18.7% |
| 2025Q1 | $-0.09 | $-0.08 | +10.9% |
| 2024Q4 | $-0.11 | $-0.11 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*